Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma

Published:2020-02-03 Issue:3 Volume:189 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Boccon‐Gibod Clémentine¹²^ORCID,Talbot Alexis¹²,Le Bras Fabien³⁴,Frenzel Laurent⁵⁶,Royer Bruno¹²,Harel Stephanie¹²,Lombion Naelle¹²,Belhadj Karim³⁴,Cuccuini Wendy⁷,Arnulf Bertrand¹²^ORCID

Affiliation:

1. Immuno‐hematology Department Hôpital Saint‐Louis APHP Paris France

2. Université Paris Diderot‐Paris VII Sorbonne Paris Cité Paris France

3. Lymphoid Malignancies Unit Henri Mondor Hospital Créteil France

4. Mondor Amyloidosis Network Créteil France

5. Department of Hematology Université Paris Descartes Hôpital Necker Enfants Malades Assistance Publique Hôpitaux de Paris Paris France

6. Institut Imagine INSERM U1163 and CNRS ERL8654 Université Paris Descartes Hôpital Necker Enfants Malades Assistance Publique Hôpitaux de Paris Paris France

7. Department of Cytogenetics Hôpital Saint‐Louis Paris France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16483

Reference9 articles.

1. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

2. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

3. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

4. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

5. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies;Blood Advances;2024-07-29

2. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

3. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency;Blood;2024-01-04

4. Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14);Pathology and Oncology Research;2023-11-10

5. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2023-11